174265-12-4Relevant articles and documents
Palladium-catalyzed ortho-C(sp2)[sbnd]H bromination of benzaldehydes via a monodentate transient directing group strategy
Yong, Qiyun,Sun, Bing,Zhang, Fang-Lin
supporting information, (2019/11/03)
A facile and efficient monodentate transient directing group strategy was developed to enable the palladium-catalyzed ortho-C(sp2)[sbnd]H bromination of benzaldehydes. A broad scope of benzaldehydes were transformed into the desired products by employing 2-amino-5-chlorobenzotrifluoride as a monodentate transient directing group, demonstrating good functional group tolerance. Mild reaction conditions and no requirement for a silver salt are also features of this strategy.
Method for preparing 2-bromo-5-chlorobenzaldehyde
-
Paragraph 0034-0037; 0058-0065; 0070-0085, (2018/04/26)
The invention discloses a method for preparing 2-bromo-5-chlorobenzaldehyde. The method is characterized by comprising the following steps: a, controlling the system temperature to be less than or equal to 10 DEG C, and sequentially and slowly dropwise adding 3-chlorobenzaldehyde and an iodine-containing catalyst in an inorganic strong-acid solvent; b, controlling the system temperature to be lessthan or equal to 15 DEG C, and adding N-bromosuccinimide NBS for multiple times in batches; and c, insulating to react for 2-10 hours, heating to 25-55 DEG C to keep on reacting for 1-6 hours, and performing post-treatment to obtain a solid product. The method has the advantages of one-step reaction, 90% high yield, simple operation, low cost, easily available raw materials, environmental friendliness and little pollution, and is suitable for the requirement for large-scale industrial production since only acid liquid is contained in waste liquid and can be neutralized in alkali liquor.
15-aryl prostaglandins as EP4 agonists, and methods of use thereof
-
Page/Page column 68, (2017/01/31)
The invention provides compositions and methods for reducing healing wounds and reducing scars and blemishes. The compositions and methods of the invention include at least one EP4 agonist set forth herein. Wounds and or scars that can be treated by the compositions and methods of the invention can arise from events such as surgery, trauma, disease, mechanical injury, burn, radiation, poisoning, and the like.